Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups

• Thozhukat Sathyapalan,
• Andrei-Mircea Catarig,
• Patrick Holmes,
• Jean-François Yale,
• Ulrik Bodholdt,
• Sergiu Catrina,
• Alice Clark,
• Neda Rajamand Ekberg,
• Umut Erhan,
• Søren Tang Knudsen,
• Joanne Liutkus,
• Bernd Schultes,
• Gottfried Rudofsky

Affiliations

Thozhukat Sathyapalan

Diabetes and Endocrinology, Hull University Teaching Hospitals NHS Trust, Hull, UK

Andrei-Mircea Catarig

Medical and Science, Novo Nordisk A/S, Søborg, Denmark

Patrick Holmes

General practitioner

Jean-François Yale

Royal Victoria Hospital, McGill University Health Centre, Montreal, Quebec, Canada

Ulrik Bodholdt

Kastruplægerne, Kastrup, Denmark

Sergiu Catrina

Karolinska Institutet, Stockholm, Sweden

Alice Clark

Novo Nordisk AS, Søborg, Denmark

Neda Rajamand Ekberg

Karolinska Institutet, Stockholm, Sweden

Umut Erhan

Novo Nordisk AS, Søborg, Denmark

Søren Tang Knudsen

Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark

Joanne Liutkus

Joanne F. Liutkus Medicine Professional Corporation, Cambridge, Ontario, Canada

Bernd Schultes

Metabolic Center St. Gallen, friendlyDocs, St. Gallen, Switzerland

Gottfried Rudofsky

Clinic for Endocrinology and Metabolic Diseases, Cantonal Hospital Olten, Olten, Switzerland